COSMIC-312
Regimen
- Experimental
- cabozantinib 40 mg + atezolizumab (combo arm); cabozantinib 60 mg monotherapy arm
- Control
- sorafenib
Population
Advanced hepatocellular carcinoma, no prior systemic therapy
Key finding
mPFS 6.8 vs 4.2 mo (HR 0.63, p=0.0012) — PFS endpoint met; interim mOS 15.4 vs 15.5 mo (HR 0.90, p=0.44) — **OS endpoint NOT met**; illustrates PFS/OS disconnect in HCC; etiology HBV ~31%, HCV ~29%, non-viral ~40%
Source: PMID 35798016